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Interpreted Correctly?
Baruch A Brody, PhD, Carol M Ashton, MD, MPH, Dandan Liu, Youxin Xiong, Xuan Yao, BA,
Nelda P Wray, MD, MPHBACKGROUND: Many published accounts of clinical trials report no differences between the treatment arms,
while being underpowered to find differences. This study determined how the authors of
these reports interpreted their findings.
STUDY DESIGN: We examined 54 reports of surgical trials chosen randomly from a database of 110 influential
trials conducted in 2008. Seven that reported having adequate statistical power (b  0.9)
were excluded from further analysis, as were the 32 that reported significant differences
between the treatment arms. We examined the remaining 15 to see whether the authors inter-
preted their negative findings appropriately. Appropriate interpretations discussed the lack of
power and/or called for larger studies.
RESULTS: Three of the 7 trials that did not report an a priori power calculation offered inappropriate
interpretations, as did 3 of the 8 trials that reported an a priori power < 0.90. However, we
examined only a modest number of trial reports from 1 year.
CONCLUSIONS: Negative findings in underpowered trials were often interpreted as showing the equivalence of
the treatment arms with no discussion of the issue of being underpowered. This may lead
clinicians to accept new treatments that have not been validated. (J Am Coll Surg 2013;
216:158e166.  2013 by the American College of Surgeons)Treatments are often recommended for clinical practice
after trials find no significant differences between these
treatments and the current standard of care. However,
these trials may be conducted with insufficient power.
Under conditions of insufficient power, one must be care-
ful in the interpretation of the meaning of a finding of no
difference between treatment arms; ineffective treatments
might mistakenly be recommended because the data show
no difference between the treatment arms. Can one
conclude that there really is no difference in the treat-
ments, so the recommendation of the new treatment is
justified, or is the lack of a difference simply related to
the small sample sizes, so the introduction of the new
treatment is not justified?t #
pted
ong,
and
gery
ilos-
158The extent of this problem has not been adequately
explored. An opportunity to study it arose as part of
a larger project we are conducting to analyze the meth-
odologic and ethical strengths and weaknesses of influen-
tial comparative surgical trials whose results were reported
between 2000 and 2008.1 In a sample of 290 surgical
trials, we observed 130 that did not report a priori power
calculations or left out important components of the
power calculation. However, in many cases, the authors
of these trials claimed no significant differences between
the treatment arms and made clinical recommendations
to introduce the treatment.
We therefore undertook this study to evaluate how the
findings of “no significant differences between the treat-
ment groups” were interpreted in trials that either did
not report an adequate a priori statistical power (and
may not have based their sample sizes on power consider-
ations) or did report power calculations but with sample
sizes that conferred low power (b < 0.90) to detect real
differences between treatment groups.METHODS
This study is part of a project funded by the National
Institutes of Health called “Ethical and Methodological
Standards for Clinical Trials of Invasive Procedures.”2,3ISSN 1072-7515/12/$36.00
http://dx.doi.org/10.1016/j.jamcollsurg.2012.09.015
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disseminate reasonable contemporary ethical and meth-
odologic standards for trials of surgical and minimally
invasive procedures. One step of the project was an anal-
ysis of the methodologic and ethical strengths and weak-
nesses of 290 influential comparative surgical trials whose
results were reported between 2000 and 2008.1
Sample
The trials reviewed for this study comprised a 50%
random sample of the 110 trials from the parent study
that were published in 2008 (the most recent year avail-
able). Fifty-four were selected for review. For each trial,
we reviewed only the publication in which the main
results were reported.
Development of the review process
The first step was to systematize the processes of review
and the data elements to be extracted from the trial
reports, which would enable us to assess the actual trial
results and the authors’ interpretations of the findings
of their trials. To achieve this, we first selected from the
parent database of trial dossiers 5 trials that varied by
important characteristics such as funding source, single
or multiple performance sites, superiority or noninferior-
ity design, type of control (alternative invasive procedure
or noninvasive comparison group), allocation method,
and methods of blinding. All 5 publications were then
independently read by each of the 3 senior investigators
and each of the 3 research assistants. Each reviewer out-
lined a process of review and noted those variables they
believed important to evaluate findings and authors’
interpretations. The 6 investigators then met to discuss
their proposed review procedures and data elements.
The following processes and data abstraction for the arti-
cles were agreed on and used with the 54 trial reports.
Each report would be read independently by 2 of the
research assistants, who would record in spreadsheets
the following data elements: publication title; journal;
trial objectives as reported by the authors; trial intent
(test of superiority or noninferiority); a description of
the intervention and the control; a description of the
study population studied, including the number of
subjects in each treatment arm; the primary outcome
(the endpoint designated by the author as the primary
outcome, or, if a power calculation was reported, the
outcome used in that calculation); the report of a power
calculation for the primary outcome, and if present, the
components of the power calculation that were reported;
all secondary outcomes and any power calculations for
these variables; the direction, magnitude and statistical
significance of all findings; the authors’ interpretation ofthe findings (abstracted from the abstract and/or the
discussion section); and our assessment of the appropri-
ateness of the authors’ interpretation. Each of the 54 trials
was also classified as to whether it met 1 or more of our
categories of specific interest, namely, the absence of
reported a priori statistical power calculations, or low
statistical power (defined as b < 0.090).
Assessment of the appropriateness of authors’
interpretations
There were no issues of interpretation in trials that showed
a statistically significant difference between the 2 arms.
Specific criteriawere developed for assessing the appropriate-
ness of authors’ interpretation of trials finding no significant
differences between treatment groups. First, for trials not
reporting a priori power calculations or with low statistical
power (b < 0.90), and finding “no significant differences”
between treatment groups, the authors of the trial report
had to include an explicit consideration of power in order
for us to classify the interpretation as correct. We judged
these reports to have an appropriate interpretation of the
findings if the authors explicitly discussed the lack of power
or small sample sizes as a potential explanation of the find-
ings or if they recommended larger studies to confirm their
findings. We judged authors’ interpretations to be flawed
when the authors interpreted “no significant difference”
findings as indicating that the interventions in the study
were equivalent or just as good as one another and failed
to discuss statistical power or small sample sizes, or failed
to recommend larger studies to confirm the findings.
Review process
To ensure consistency in data element recognition, each
research assistant re-reviewed and abstracted the 5 test
trial reports. These data were then presented and dis-
cussed at face-to-face meetings with the 3 senior investi-
gators until all discrepancies were resolved and explained.
After training was completed, each of the 54 trial
reports was independently reviewed and abstracted by 2
research assistants, who then met to discuss their findings.
Any discrepancies were resolved or referred to the senior
investigators to adjudicate.
To ensure the validity of the data, throughout the
review process during face-to-face meetings of the entire
team, 1 or more of the 3 senior investigators reviewed
all abstracted data for clarity and internal consistency.
Questions regarding the data were resolved by re-review
of the primary article. Finally, a senior investigator
re-reviewed the classification of all 54 articles as to whether
the articles did not report a priori power or had low power
and claimed no significant difference and confirmed
whether or not a misinterpretation was present.
160 Brody et al Interpretation of Negative Surgical Trials J Am Coll SurgRESULTS
A high proportion of the 54 surgical trials (47 of 54)
either did not report statistical power calculations or
reported them and were underpowered. Of the 54
surgical trials, 23 (42.6%) did not report a priori power
calculations. Twenty-four (44.4%) reported a power
< 0.9; only 7 (13.0%) reported a power  0.9. Approx-
imately one-third (15) of the reports that either did not
include an a priori power calculation or had low power
claimed no significant difference, and therefore met our
criteria for further review (Fig. 1).
Of the 7 articles4-10 that claimed no significant differ-
ence with unreported a priori power calculations, we
judged the authors’ interpretation regarding a claim of
no significant difference as appropriate in 4 (Table 1).
Three of these noted that small sample size and low
power could be an explanation of the null finding and
recommended that larger trial studies be undertaken to
confirm the findings. One study only recommended
a larger study to confirm their results. In 3 trials, however,
the authors interpreted the finding of “no significant
difference” as meaning the 2 treatments are equally
good alternatives and did not consider low power as
a potential explanation. Our post hoc calculations of
the power of these studies showed that the power was
very limited, even to detect substantial differences
between the treatment groups.Figure 1. Trials that met our criteria for further review to evaluate theThe data on the 8 trials11-18 that met our criteria of low
a priori power (<0.9), although finding no significant
difference between treatment groups, are provided in
Table 2. Seven of these trials reported a power  0.8
and the other a power of 0.7. Four of these trials were
judged to have appropriate interpretation of the null
finding because authors discussed the limitation of power
and suggested other studies (n ¼ 3) or just suggested
a larger study (n ¼ 1). An additional trial was judged
to have an appropriate interpretation because the investi-
gators entered far more patients than the power calcula-
tion suggested would be needed, strengthening the
claim of no significant difference. The authors of the 3
remaining trials did not consider low power as a potential
explanation of their findings and did not suggest larger
studies; they inappropriately interpreted their finding as
meaning the 2 treatments are equally good alternatives.
Authors made inappropriate interpretations in 6 of the
15 (40%) trials we reviewed in which no significant
differences were observed between treatment groups.
They mistakenly concluded that the 2 treatments are
equally good alternatives.
DISCUSSION
Of the 54 trials we reviewed, only 7 (16%) reported
adequate power to detect statistically significant differ-
ences between treatment groups. Of the 47 that didappropriateness of the authors’ interpretations of their findings.
Table 1. Characteristics of Clinical Trials that Did Not Report an A Priori Sample Size and Power Calculation and that Did Not Find a Significant Difference
Between Treatment Groups
Study question Primary endpoints
Secondary
endpoints, n Authors’ conclusion
Our evaluation of the authors’
interpretation
Evaluation of 3 treatments: simple
auripuncture plus aspiration
(n ¼ 45); tympanic membrane
fenestration with cauterization
(n ¼ 45); or myringotomy plus
grommet insertion (n ¼ 45) for
postirradiation otitis media
Not designated 4 “The three methods used here each have
advantages and disadvantages. In
conclusion, we believe that a step by step
approach should be adopted in choosing
treatment methods. That is, we should use
auripuncture first and then consider the
other methods only if the former is
inadequate.”4
Interpretation inappropriate: power
limitations were not discussed and
large studies were not recommended.
The authors claim equivalency even
though all variables trend in favor of
one intervention. Our calculations
show the study had only a 50% power
to detect a 37% increase in cure rate
from 40% to 55%.
Restrictive use of episiotomy
(n ¼ 101) vs routine use
of episiotomy (n ¼ 99)
Extensive perineal
tearing involving the
anal sphincter
(third- or fourth-
degree tears)
19 “The pilot study does not provide conclusive
evidence that a policy of routine episiotomy
is better or worse than a restrictive policy.
A definitive randomized controlled trial is
feasible but will require a large sample size
to inform clinical practice.”5
Interpretation appropriate: power
limitation of this “pilot study”
discussed. A definitive randomized
controlled trial was recommended and
the sample size needed for that trial
calculated.
High-frequency radiosurgery
(n ¼ 26) vs conventional
diathermy (n ¼ 38) to reduce
complications after skin-saving
mastectomy
Not designated 3 “This study shows that high-frequency
radiosurgery is comparable to
conventional diathermy in terms of
complication rates. Further prospective
randomized studies are required to
critically evaluate the role of
radiofrequency surgery and other newly
developed dissection methods.”6
Interpretation appropriate: though power
limitations are not discussed, larger
studies are recommended.
Comparison of the “inside-out”
(n ¼ 50) and “outside-in”
(n ¼ 50) transobturator-tape
procedures for female stress
urinary incontinence (SUI).
Not designated 22 “We would like to conclude that in our series,
tension-free vaginal tape obturator (TVT-
O) and transobturator-tape (TOT) appear
equally effective for female SUI. However,
this study was unable to identify
a difference between the two procedures.
The findings may be due to the
underpowered nature of the study. Ideally,
large well-constructed randomized
controlled trial with longer follow-up
period is necessary.”7
Interpretation appropriate: power
limitations were addressed and larger
studies recommended.
PAS-Port (n ¼ 51)
vs conventional
hand-sewn (n ¼ 48) vein
anastomosis to the aorta
Designated 2: patency at
discharge and patency
after 1 year
3 “This prospective randomized study
demonstrated excellent short and midterm
patency in both the hand-sewn and PAS-
Port grafts. The PAS-Port system allowed
for the rapid, safe, and effective creation
of a proximal anastomosis without the
need to clamp the aorta. Based on this
study we consider this product a valid
alternative for proximal anastomosis.”8
Interpretation inappropriate: power
limitations were not discussed and
larger studies were not recommended.
The authors claim equivalency even
though all variables trend toward one
intervention. Our calculations show
that the study had only a 50% power
to detect a 50% reduction in
complications: 25% to 12.5%
(Continued)
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162 Brody et al Interpretation of Negative Surgical Trials J Am Coll Surgnot, 15 (33%) reported no significant difference between
the 2 groups. These are the studies of greatest concern
because authors may make inappropriate clinical recom-
mendations based on the findings. In fact, 6 of these 15
(40%) drew the inappropriate conclusions that the 2
treatments being studied are equally good alternatives.
This mistake may have resulted in clinicians adopting
treatments with inadequate justification, potentially
leading to adverse or suboptimal outcomes for their
patients.
As early as 1978, Frieman and colleagues19 called atten-
tion to the problem of “negative trials” with low power,
which could have missed important differences between
treatment arms. Since then, an extensive debate has raged
over the ethics of conducting underpowered trials, with
some20 claiming that they are unethical except in certain
special circumstances and others21 offering a more
positive evaluation of them as long as the reports of the
published trials properly interpret the findings. Many
studies22,23 have reported on the prevalence of underpow-
ered surgical trials as well as trials in other areas of medi-
cine.24 What makes our study different is that we report
on how these underpowered trials were interpreted in
the published reports. Our crucial finding is that the
underpowered trials are often misinterpreted in the pub-
lished reports of their findings. Others have offered
preliminary data suggesting that these misinterpretations
are often adopted even by those well-trained in statistics.25
The major implication of our study is that treatments
are being recommended that may be inferior to the
current standard of care. Clinicians have to take care to
evaluate statistical power issues before accepting recom-
mendations found in the literature about potential treat-
ment options. The problem, however, lies with the
trialists who, knowingly or unknowingly, misrepresent
the meaning of underpowered trials and with the journal
editors who publish flawed reports of trials. Patients may
receive inadequate treatment unless clinicians, researchers,
reviewers, and journal editors are more careful about the
design and interpretation of underpowered trials.
Limitations
One major limitation of this study is that only surgical
trials were reviewed, given the focus of our project. We
have no way of evaluating whether the problem is greater
or less in trials of nonsurgical interventions. Furthermore,
because we studied only trials from 2008, we cannot
determine how pervasive the issue was before 2008 and
whether it has improved since then.
The most significant limitation to our study is the
sample size. We studied only 54 surgical trials. Even
though these were influential studies, which might be
Table 2. Characteristics of Surgical Trials with an APriori Power0.90 toDetect aDifference and Findings of NoSignificant DifferenceBetween TreatmentGroups
Study question Primary endpoints
Secondary
endpoints, n Authors’ conclusion
Our evaluation of the authors’
interpretation
Comparison of bilateral internal
thoracic artery (BITA)
revascularization using in situ
(n ¼ 152) or y graft (n ¼ 152)
configurations
Major adverse cerebro-
cardiovascular events
13 “Excellent patency rates were achieved using
both BITA configurations with no significant
differences in terms of major adverse cerebro-
cardiovascular events up to 19 months
postoperatively or inferior temporal artery
(ITA) patency.”11
Interpretation inappropriate: power
calculation incorrectly conducted on
a secondary endpoint, graft patency.
Our calculation of power on the
primary outcome showed the study
had only a 46% power to detect a 50%
reduction in major adverse cerebro-
cardiovascular events. The low power
was not discussed as an explanation for
the claim of equivalency and larger
confirmatory studies were not
recommended.
Transobturator tape (n ¼ 82)
compared with tension-free
vaginal tape (TVT; n ¼ 88)
for the treatment of stress urinary
incontinence
A composite endpoint of
several parameters
assessing the presence
or absence of abnormal
bladder function
14 “The transobturator tape is not inferior to TVT
for the treatment of stress urinary
incontinence and results in fewer bladder
perforations. Both the objective and
subjective cure rates in both groups were
high, and therefore no significant differences
could be detected. Larger studies are needed
to evaluate the relative risk of less common
but potentially severe complications.”12
Interpretation appropriate: study
appropriately identified the limitations
of small sample size and recommend
larger studies were recommended in
the future.
Tension-free vaginal tape obturator
(TVT-O; n ¼ 132) vs tension-
free vaginal tape (TVT; n ¼ 136)
Cure rates 14 “Both the objective and subjective cure rates in
both groups were high, and therefore no
significant differences could be detected. Both
procedures seem to be equally highly
successful at 12 months postoperatively. This
randomized trial shows that classic TVT and
TVT-O perform equally.”13
Interpretation inappropriate: study
claimed equivalency with no
discussion of power limitation and
does not recommend a larger trial.
Percutaneous coronary intervention
(PCI) with distal protection
(I, n ¼ 312), percutaneous
coronary intervention (PCI)
without distal protection
(C, n ¼ 314)
Complete (greater or equal
to 70%) ST-segment
resolution
6 “The routine use of distal protection by
a filterwire system during primary PCI does
not seem to improve microvascular perfusion,
limit infarct size, or reduce the occurrence of
major adverse cardiac and cerebrovascular
event (MACCE). The results of the present
study demonstrate that routine use of
adjunctive mechanical devices cannot be
advocated during PCI treatment of patients
with ST-segment elevation myocardial
infarction (STEMI).”14
Interpretation appropriate: their
calculations show that 450 patients
were needed for an 80% power. Study
randomized 626 patients to increase
power. Claim of equivalency
warranted.
(Continued)
V
o
l.
2
1
6
,
N
o
.
1
,
Ja
n
u
a
ry
2
0
1
3
B
rody
et
al
In
te
rp
re
ta
tio
n
o
f
N
e
ga
tive
S
u
rgica
l
Tria
ls
1
6
3
Table 2. Continued
Study question Primary endpoints
Secondary
endpoints, n Authors’ conclusion
Our evaluation of the authors’
interpretation
Cognitive outcomes after off-pump
coronary artery bypass grafting
(CABG; I, n ¼ 61), on-pump
CABG (C, n ¼ 59)
Cognitive dysfunction at
12 mo after surgery
7 “There were no significant differences in the
incidence of cognitive decline between the
off-pump (19%) and on-pump (9%) group.
The detection of a difference between 19%
and 9% would require approximately 400
patients. Hence there is a need for larger
multi-center trials.”15
Interpretation appropriate: the primary
power calculation, however, was
inappropriate because the rates of
adverse outcomes used (50% and
20%) were not justified. The study
does claim equivalency with low
power; however, it notes the
limitations of the small sample size
and recommends larger studies.
CABG with intramuscular (n ¼ 21)
or intracoronary (n ¼ 21) bone
marrow cells (BMC) or standard
CABG (n ¼ 20) without
intramuscular or intracoronary
bone marrow cells
Improvement in systolic
function of scar segments
6 mo after treatment
10 “Injection of autologous BMCs directly into the
scar or into the artery supplying the scar is
safe but does not improve contractility of
nonviable scarred myocardium, reduce scar
size, or improve left ventricular function
more than CABG alone.”16
Interpretation inappropriate: there is
a trend toward a negative effect of the
bone marrow treatments, yet a strong
claim of equivalency is given with no
discussion of the limitations of lack of
power, nor were larger studies
recommended.
Carotid artery stenting with
(n ¼ 18) or without (n ¼ 18)
cerebral protection.
New ischemic injury 4 “Our data suggest that distal protection filters
may not be as effective as expected in
reducing microemboli compared with
stenting without any filter protection. New
defects on MRI were noted in 13/18 (72%)
of those with protective devices versus 8/18
(44%) without. Larger studies are clearly
warranted.”17
Interpretation appropriate: the study was
stopped by the Data Safety
Monitoring Board due to unsuccessful
recruitment. The study power
calculations suggested enrollment
should be 45 in each group, but
enrollment of only 18 in each group
was achieved. Study failed to discuss
the limitations of low power, however
the authors did recommend larger
studies.
Routine (n ¼ 101) vs provisional
T-stenting (n ¼ 101) in the
treatment of de novo coronary
bifurcation lesions
Percent stenosis of the side
branch at 9 mo
5 “As our key result we did not find that routine
T-stenting reduced the risk of the side-branch
restenosis. The per cent diameter stenosis in
the side branch after provisional T-stenting
was lower than projected, which reduces
power to detect the projected 33% reduction
in per cent diameter stenosis by routine T-
stenting.”18
Interpretation appropriate: lack of power
considered and a larger study
published just as the results of this
study made available were discussed.
Further, the authors note the high rate
of stent stenosis and recommend
further studies.
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trials, generalizing from these results to all surgical trials
would be problematic. We have established the existence
of these serious misinterpretations. Additional studies,
with larger sample sizes, would be required to more firmly
estimate the extent of this problem in the general surgical
literature.
Also, we have called attention to the possibility that
these misinterpretations may lead to inappropriate
changes in actual practice. Our study was not designed
to determine whether these changes actually took place.
Further studies, involving billing or coding data sets
from before and after the publication, would be required
to show that these changes actually took place.
CONCLUSIONS
It is time to put an end to this problem. Journal editors
and reviewers should pay more attention to authors’
interpretations of underpowered studies, rejecting articles
that contain such misrepresentations or requiring them to
be revised. The clinical research community needs to
better educate potential researchers about the importance
of running adequately powered trials and about properly
interpreting trials that are underpowered. Clinicians need
to evaluate issues of power and interpretation before
accepting recommendations emanating from clinical
trials. All these measures are necessary if patients are to
benefit from clinical trials and not be exposed to potential
harm by being subjected to invasive procedures, which
however promising, have not yet been shown to be supe-
rior, or at least not inferior, to the standard of care.
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